1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension
    Meeting Abstract

    Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S. E.; Flowers, C.; Kim, T. M.; McMillan, A.; Ozcan, M.; Safar, V.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Results of a phase 1 open label dose escalation trial of AB-205 (allogeneic engineered endothelial cell therapy) in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT)
    Meeting Abstract

    Scordo, M.; Budde, L. E.; Abedi, M.; Mulroney, C.; Fakhri, B.; Pawarode, A.; Dholaria, B.; Kavalerchik, E.; Aggarwal, S. K.; Qazilbash, M. H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma: Primary efficacy and safety analysis of the phase 2 CheckMate 436 study
    Meeting Abstract

    Santoro, A.; Moskowitz, A. J.; Ferrari, S.; Carlo-Stella, C.; Fanale, M. A.; Francis, S.; Sacchi, M.; Savage, K. J.
    Blood (2020)

    Fulltext@MSK | Save
  • Development and baseline characterization of a thrombosis risk alert tool: A quality assessment project
    Meeting Abstract

    Sathe, C. M.; Poon, C.; Sarasohn, D. M. M.; Gilbert, L.; Khorana, A. A.; Mantha, S.; Soff, G. A.
    Blood (2020)

    Fulltext@MSK | Save
  • Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Ruan, J.; Moskowitz, A. J.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Rahim, R.; Song, W.; Van Besien, K.; Horwitz, S. M.; Rutherford, S. C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed to prior alkylator therapy-subgroup analysis
    Meeting Abstract

    Rodríguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Worldwide examination of patients with CLL hospitalized for COVID-19
    Meeting Abstract

    Roeker, L. E.; Scarfo, L.; Chatzikonstantinou, T.; Abrisqueta, P.; Eyre, T. A.; Cordoba, R.; Prat, A. M.; Villacampa, G.; Leslie, L. A.; Koropsak, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in 55 patients (pts) with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD)-subgroup analysis
    Meeting Abstract

    Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save